Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide plus exemestane as neoadjuvant therapy for early hormone receptor–positive breast cancer
ChiCTR2100046678Phase 4Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tucidinostat and exemestane in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Proportion of patients with breast cancer neoadjuvant endocrine score = 0 after surgery. Started May 2021; status: recruiting.
02
Drugs
tucidinostatexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100046678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046678.